Presented at #ESCCongress:
In patients with severe tricuspid regurgitation and heart failure, transcatheter tricuspid-valve repair plus medical therapy was superior to medical therapy alone in reducing hospitalizations for heart failure and deaths. Full TRIC-I-HF trial results: nej.md/4ilZJGr@escardio
Can anchor-#BASILICA/#UNICORN help prevent CO during #TAVR? In a multicenter study of high-risk patients, investigators evaluated feasibility, procedural success, & 30-day outcomes of this leaflet laceration technique before TAVR.
Read more in #JACCINT: jacc.org/doi/10.1016/j.jcin.…
🫀 Calling all cardiac surgeons, trainees, & multidisciplinary heart teams!
Share your surgical cases, innovative techniques, & clinical lessons in #JACCCaseReports. Our July Call for Submissions is now open.
📅 Submit by July 31: jacc.org/call-for-papers/cas…#ACCSurgeons#cvSurg
DONT'T WAIT until the 3/11 deadline! Submit your AMYLOID cases or 4 Corners vignette, multidisciplinary team discussion, flash debates, beyond the guidelines and viewpoints NOW to @JACCJournals#JACCCaseReports! This is a sponsored session where the selected top papers for this special issues get their open access fee waived. Thank you to our guest Editor-in-Chief Dr. Joshua Mitchell for curating this special issue on such an important and novel topic in cardiovascular medicine.
More details here:
jacc.org/call-for-papers/cas…
JUST OUT! #JACCINT@JACCJournals on long-term outcomes of SAPIEN3 MVIV MVIR VIMAC #TMVR. As expected, MVIV did much better than MVIR and VIMAC in all-cause and CV mortality. Median follow-up 3ys (up to 8y) with ~7% severe SVD after 5y and ~10% TMVR failure after 4y. Depends on how you see it, I see this as sobering outcomes: MVIR and VIMAC should be offered only in inoperable patients with limited life expectancies, given poor survival and limited valve durability. MVIV has better outcomes, but need to follow re: SVD and TMVR failure and may end up being a bridge to reop MVR especially in younger patients. 5y durability data of native TMVR are emerging (Intrepid, Tendyne), will see how they fare vs balloon-expandable TMVR in failed valves, rings, MAC.
Thoughts and comments?
jacc.org/doi/full/10.1016/j.…
JUST OUT on my @YouTube Channel! My tips and tricks on how to optimize your @powerpoint presentations, so the videos, images show flawlessly; how to crop images, import screen shots, optimize image and video qualities and color/contrasts, trim and play videos synchronously, play multiple videos in sync without manually clicking them, and in loops (especially useful for echo and angio videos), how to optimize the PPTX file size and make all the videos embedded and compatible (no more glitches and videos can't play on the podium), and how to save your slides into individual high-res image files for manuscript submissions to academic journals.
youtube.com/watch?v=cPi1Fq0K…
🫀 Severe aortic stenosis + extremely large annulus? Read about a valve-in-valve approach using J-Valve as an anchor. A first-of-its-kind solution pushing the limits of structural heart interventions! ⬇️
cjcopen.ca/article/S2589-790…#CJCO#OpenAccess
As our patients are getting more and more complex, we need wide variety of ideas, insights, and techniques for our best patient care. Cannot agree more with @TsuyoshiKaneko1, #PCRTokyo is also waiting for contemporary cardiac surgeons and imagers! @PCRonline
Come and join one of the best Valve meetings in the world's best city!! Cardiac Surgeons should join as the key members of the Heart Team. @OhnoTuri@GilbertTangMD@PCRonline#PCRTokyo